Author, as appears in the article.: Aragones, Gerard; Alonso-Villaverde, Carlos; Pardo-Reche, Pedro; Rull, Anna; Beltran-Debon, Raul; Rodriguez-Gallego, Esther; Fernandez-Sender, Laura; Camps, Jordi; Joven, Jorge
Department: Medicina i Cirurgia; Bioquímica i Biotecnologia
URV's Author/s: ARAGONÈS BARGALLÓ, GEMMA / Aragonès Bargalló, Gerard / Beltrán Debón, Raúl Alejandro / Camps Andreu, Jorge / CAMPS RATERA, JOSEP / Joven Maried, Jorge / Pardo Reche, Pedro Antonio / Rodríguez Gallego, Esther / RULL AIXA, ANNA
Keywords: Triglyceride-rich lipoproteins; Therapy; Necrosis-factor-alpha; Lipid disorders; Glucose-metabolism; Genetic polymorphisms; Density-lipoprotein cholesterol; Arterial inflammation; Apolipoprotein-b metabolism; A-i
Abstract: Background: The recently observed association between the APOC3-related rs10892151 polymorphism and serum triglyceride levels has prompted us the possibility to explore whether this genetic variant may play a major role in human immunodeficiency virus (HIV)/antiretroviral therapy-induced dyslipidemia.Methods: We determined the rs10892151 genotype distribution and serum apolipoprotein (apo) C-III concentration in a group of HIV-infected patients (n = 208) and in a group of age and sex-matched healthy volunteers (n = 200). Circulating lipid and lipoprotein levels were followed for 12 months after antiretroviral treatment initiation in the HIV-infected group.Results: There were no significant variations in the frequency of the A allele between the healthy and HIV-infected groups (7.5 vs. 8.6%, respectively; p = 0.7); additionally, the A allele was not related to serum apo C-III concentration. However, among patients receiving protease inhibitor (PI) treatment, carriers of the A allele had significantly increased serum triglyceride (5.76 ± 2.54 mmol/L) and total cholesterol (6.63 ± 2.85 mmol/L) concentrations together with depressed levels of HDL-cholesterol (0.75 ± 0.3 mmol/L) when compared with patients not carrying the allele (2.43 ± 1.32, 5.2 ± 2.17 and 1.24 ± 0.4 mmol/L, respectively) at the end of the study. This effect was only evident for HDL-cholesterol concentration when patients were treated with non-nucleoside reverse transcriptase inhibitors (1.05 ± 0.4 vs. 1.28 ± 0.4 mmol/L).Conclusions: The A allelic variant of the rs10892151 polymorphism is not associated with serum apo C-III concentration, but predisposes HIV-infected patients to less favorable lipid profile, particularly in those patients treated with PIs. © 2011 Aragonès et al; licensee BioMed Central Ltd.
Thematic Areas: Saúde coletiva; Química; Odontología; Nutrição; Medicina iii; Medicina ii; Medicina i; Matemática / probabilidade e estatística; Interdisciplinar; Genetics (clinical); Genetics & heredity; Genetics; Farmacia; Engenharias iv; Engenharias iii; Ciências biológicas iii; Ciências biológicas ii; Ciências biológicas i; Biotecnología; Biodiversidade
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 14712350
Author's mail: pedroantonio.pardo@urv.cat; jorge.camps@urv.cat; jorge.joven@urv.cat; esther.rodriguez@urv.cat; gerard.aragones@urv.cat; raul.beltran@urv.cat
Record's date: 2025-02-08
Paper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-12-120
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Paper original source: Bmc Medical Genetics. 12 120-
APA: Aragones, Gerard; Alonso-Villaverde, Carlos; Pardo-Reche, Pedro; Rull, Anna; Beltran-Debon, Raul; Rodriguez-Gallego, Esther; Fernandez-Sender, Laura; (2011). Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism. Bmc Medical Genetics, 12(), 120-. DOI: 10.1186/1471-2350-12-120
Article's DOI: 10.1186/1471-2350-12-120
Entity: Universitat Rovira i Virgili
Journal publication year: 2011
Publication Type: Journal Publications
Repositori URV